retatrutide triple agonist weight loss trial New Phase 3 data just dropped 👀 Eli Lilly's reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats 🚨The first phase 3 retatrutide

Looking at retatrutide specifically across the vendors they have tested, NuScience rating of A (Great) with 8 samples and a 7.2 average score places it in the upper tier

** Our GLP weight loss program does not require participants to have diabetes

Although Hogan et al

The clinical trial reported percentage weight loss rather than absolute weight, so researchers should calculate expected absolute weight changes based on the starting weight of their research subjects when designing study endpoints

PlexusDx dispenses from licensed 503A compounding pharmacies at $189/month for Semaglutide Injection and $289/month for Tirzepatide Injection, month to month, so the two models can be compared line for line

Read the full breakdown in what the FDA's July 30 deadline means for compounded semaglutide